已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke

医学 特奈特普酶 溶栓 改良兰金量表 闭塞 冲程(发动机) 随机对照试验 纤溶剂 内科学 麻醉 组织纤溶酶原激活剂 缺血 缺血性中风 心肌梗塞 机械工程 工程类
作者
Bruce Campbell,Peter Mitchell,Leonid Churilov,Nawaf Yassi,Timothy Kleinig,Richard Dowling,Bernard Yan,Steven Bush,Vincent Thijs,Rebecca Scroop,Marion Simpson,Mark Brooks,Hamed Asadi,Teddy Y. Wu,Darshan Shah,Tissa Wijeratne,Henry Zhao,Fana Alemseged,Felix Ng,Peter Bailey
出处
期刊:JAMA [American Medical Association]
卷期号:323 (13): 1257-1257 被引量:227
标识
DOI:10.1001/jama.2020.1511
摘要

Importance

Intravenous thrombolysis with tenecteplase improves reperfusion prior to endovascular thrombectomy for ischemic stroke compared with alteplase.

Objective

To determine whether 0.40 mg/kg of tenecteplase safely improves reperfusion before endovascular thrombectomy vs 0.25 mg/kg of tenecteplase in patients with large vessel occlusion ischemic stroke.

Design, Setting, and Participants

Randomized clinical trial at 27 hospitals in Australia and 1 in New Zealand using open-label treatment and blinded assessment of radiological and clinical outcomes. Patients were enrolled from December 2017 to July 2019 with follow-up until October 2019. Adult patients (N = 300) with ischemic stroke due to occlusion of the intracranial internal carotid, \basilar, or middle cerebral artery were included less than 4.5 hours after symptom onset using standard intravenous thrombolysis eligibility criteria.

Interventions

Open-label tenecteplase at 0.40 mg/kg (maximum, 40 mg; n = 150) or 0.25 mg/kg (maximum, 25 mg; n = 150) given as a bolus before endovascular thrombectomy.

Main Outcomes and Measures

The primary outcome was reperfusion of greater than 50% of the involved ischemic territory prior to thrombectomy, assessed by consensus of 2 blinded neuroradiologists. Prespecified secondary outcomes were level of disability at day 90 (modified Rankin Scale [mRS] score; range, 0-6); mRS score of 0 to 1 (freedom from disability) or no change from baseline at 90 days; mRS score of 0 to 2 (functional independence) or no change from baseline at 90 days; substantial neurological improvement at 3 days; symptomatic intracranial hemorrhage within 36 hours; and all-cause death.

Results

All 300 patients who were randomized (mean age, 72.7 years; 141 [47%] women) completed the trial. The number of participants with greater than 50% reperfusion of the previously occluded vascular territory was 29 of 150 (19.3%) in the 0.40 mg/kg group vs 29 of 150 (19.3%) in the 0.25 mg/kg group (unadjusted risk difference, 0.0% [95% CI, −8.9% to −8.9%]; adjusted risk ratio, 1.03 [95% CI, 0.66-1.61];P = .89). Among the 6 secondary outcomes, there were no significant differences in any of the 4 functional outcomes between the 0.40 mg/kg and 0.25 mg/kg groups nor in all-cause deaths (26 [17%] vs 22 [15%]; unadjusted risk difference, 2.7% [95% CI, −5.6% to 11.0%]) or symptomatic intracranial hemorrhage (7 [4.7%] vs 2 [1.3%]; unadjusted risk difference, 3.3% [95% CI, −0.5% to 7.2%]).

Conclusions and Relevance

Among patients with large vessel occlusion ischemic stroke, a dose of 0.40 mg/kg, compared with 0.25 mg/kg, of tenecteplase did not significantly improve cerebral reperfusion prior to endovascular thrombectomy. The findings suggest that the 0.40-mg/kg dose of tenecteplase does not confer an advantage over the 0.25-mg/kg dose in patients with large vessel occlusion ischemic stroke in whom endovascular thrombectomy is planned.

Trial Registration

ClinicalTrials.gov Identifier:NCT03340493
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
nature发布了新的文献求助10
2秒前
知足的憨人丫丫完成签到,获得积分10
2秒前
夏夏完成签到 ,获得积分10
3秒前
洁净雨柏完成签到,获得积分10
4秒前
朴素的紫安完成签到 ,获得积分10
4秒前
舒适静丹完成签到,获得积分10
4秒前
SASI完成签到 ,获得积分10
6秒前
舒适静丹发布了新的文献求助10
6秒前
科研通AI5应助彼岸花开采纳,获得50
10秒前
仙乐完成签到,获得积分10
12秒前
笨笨的荧荧完成签到 ,获得积分10
14秒前
16秒前
醉熏的荣轩完成签到 ,获得积分10
19秒前
落羽发布了新的文献求助10
21秒前
豆子应助SASI采纳,获得20
21秒前
22秒前
喬老師完成签到,获得积分10
22秒前
落羽完成签到,获得积分10
27秒前
牛奶拌可乐完成签到 ,获得积分10
28秒前
漂亮采波发布了新的文献求助10
29秒前
joanna完成签到,获得积分10
32秒前
Vincent1990完成签到,获得积分10
33秒前
zcc111完成签到,获得积分10
36秒前
37秒前
贪玩的蝴蝶完成签到 ,获得积分10
40秒前
凌七发布了新的文献求助10
40秒前
Kevin完成签到,获得积分10
43秒前
wbs13521完成签到,获得积分0
45秒前
Ava应助宁紫涵采纳,获得10
46秒前
陈陈完成签到,获得积分10
48秒前
Jasper应助哈哈哈哈采纳,获得10
53秒前
55秒前
CHSLN完成签到 ,获得积分10
55秒前
谨慎秋珊完成签到 ,获得积分10
1分钟前
Crrr完成签到,获得积分10
1分钟前
1分钟前
1分钟前
明水发布了新的文献求助10
1分钟前
江洋大盗发布了新的文献求助10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976600
求助须知:如何正确求助?哪些是违规求助? 3520674
关于积分的说明 11204470
捐赠科研通 3257316
什么是DOI,文献DOI怎么找? 1798683
邀请新用户注册赠送积分活动 877861
科研通“疑难数据库(出版商)”最低求助积分说明 806595